Payment overview · 2025
General Payments
$1,550.01
77 reported records · 22 companies
Healthcare provider profile · identity verified
Vijay Rastogi, MD
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · WARRENSVILLE HEIGHTS, OH · NPI 1457458648
Verified facts
What the public records show
CMS Open Payments records show Vijay Rastogi, MD received $1,550.01 in general payments during 2025 across 77 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 874 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 874 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $384.16 | 24.8% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $183.49 | 11.8% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $163.10 | 10.5% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.53 | 9.5% | 14 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $143.82 | 9.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.79 | 3.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.70 | 3.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $51.19 | 3.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.11 | 3.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $45.09 | 2.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.87 | 2.5% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $36.68 | 2.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.38 | 2.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.56 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.03 | 1.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.61 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.98 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.43 | 1.2% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $17.63 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.51 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.70 | 1.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.65 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,550.01 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $248.51 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $160.83 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.53 | 14 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $147.03 | 10 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $143.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $123.12 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $88.55 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.55 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.79 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $51.19 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.11 | 2 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $36.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 874 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
190 | 39 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
874 | 139 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
190 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
874 | 139 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1176 | 274 |
| Eliquis | Apixaban | 874 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 662 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 520 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 518 | 137 |
| Gabapentin | Gabapentin | 512 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 491 | 122 |
| Potassium Chloride | Potassium Chloride | 458 | 101 |
| Furosemide | Furosemide | 454 | 122 |
| Lisinopril | Lisinopril | 425 | 106 |
| Metoprolol Tartrate | Metoprolol Tartrate | 381 | 99 |
| Sertraline Hcl | Sertraline Hcl | 362 | 69 |
| Losartan Potassium | Losartan Potassium | 334 | 74 |
| Trazodone Hcl | Trazodone Hcl | 278 | 62 |
| Mirtazapine | Mirtazapine | 276 | 69 |
| Allopurinol | Allopurinol | 253 | 46 |
| Xarelto | Rivaroxaban | 251 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 51 |
| Carvedilol | Carvedilol | 233 | 61 |
| Omeprazole | Omeprazole | 217 | 67 |
| Memantine Hcl | Memantine Hcl | 200 | 34 |
| Donepezil Hcl | Donepezil Hcl | 193 | 38 |
| Jardiance | Empagliflozin | 190 | 39 |
| Finasteride | Finasteride | 182 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 48 |
| Divalproex Sodium | Divalproex Sodium | 156 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 153 | 35 |
| Torsemide | Torsemide | 153 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 30 |
| Spironolactone | Spironolactone | 148 | 43 |
| Buspirone Hcl | Buspirone Hcl | 145 | 36 |
| Simvastatin | Simvastatin | 143 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 138 | 33 |
| Metformin Hcl | Metformin Hcl | 137 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 37 |
| Levetiracetam | Levetiracetam | 127 | 24 |
| Warfarin Sodium | Warfarin Sodium | 127 | 18 |
| Famotidine | Famotidine | 120 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 32 |
| Baclofen | Baclofen | 105 | 18 |
| Farxiga | Dapagliflozin Propanediol | 104 | 19 |
| Entresto | Sacubitril/Valsartan | 102 | 15 |
| Prednisone | Prednisone | 101 | 49 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 99 | 43 |
| Montelukast Sodium | Montelukast Sodium | 99 | 19 |
| Risperidone | Risperidone | 99 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 90 | 52 |
| Januvia | Sitagliptin Phosphate | 89 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 19 |
| Myrbetriq | Mirabegron | 84 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 82 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 82 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 82 | 29 |
| Latanoprost | Latanoprost | 79 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 50 |
| Oxybutynin Chloride | Oxybutynin Chloride | 78 | 11 |
| Cephalexin | Cephalexin | 75 | 48 |
| Glimepiride | Glimepiride | 74 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 21 |
| Midodrine Hcl | Midodrine Hcl | 70 | 18 |
| Olanzapine | Olanzapine | 65 | 17 |
| Propranolol Hcl | Propranolol Hcl | 65 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 64 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 20 |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 54 | 13 |
| Meloxicam | Meloxicam | 54 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 46 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 15 |
| Digoxin | Digoxin | 46 | suppressed |
| Glipizide Er | Glipizide | 46 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | 14 |
| Methocarbamol | Methocarbamol | 46 | 27 |
| Colchicine | Colchicine | 45 | 15 |
| Tramadol Hcl | Tramadol Hcl | 45 | 25 |
| Valsartan | Valsartan | 45 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 44 | suppressed |
| Alprazolam | Alprazolam | 43 | 17 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 32 |
| Lorazepam | Lorazepam | 42 | 20 |
| Topiramate | Topiramate | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Primidone | Primidone | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 11 |
| Amoxicillin | Amoxicillin | 37 | 13 |
| Enulose | Lactulose | 37 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Creon | Lipase/Protease/Amylase | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 32 | 32 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 31 | suppressed |
| Glipizide | Glipizide | 31 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 12 |
| Azithromycin | Azithromycin | 29 | 22 |
| Levofloxacin | Levofloxacin | 29 | 24 |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 14 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Indapamide | Indapamide | 26 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Ursodiol | Ursodiol | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Ozempic | Semaglutide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Budesonide Dr | Budesonide | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 15 |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Motegrity | Prucalopride Succinate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fiasp Penfill | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tobramycin Sulfate | Tobramycin Sulfate | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,550.01 · 77 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, AMYVID, BREZTRI, BRILINTA, CAMZYOS, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, GVOKE HYPOPEN, KISUNLA, Kerendia, Korlym, NURTEC ODT, OFEV, OTEZLA, Ozempic, PAXLOVID, PROVENGE, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VYNDAMAX, XIFAXAN, YUPELRI | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error